Equity Brief · Healthcare2026-05-20
TMO·Healthcare

Thermo Fisher Scientific Inc

I · Analyse IA

En bref

Thermo Fisher supplies the tools, chemicals, and services that pharmaceutical companies and research labs need to discover drugs, manufacture medicines, and run diagnostic tests. They operate across four segments: Life Sciences Solutions (research reagents and instruments), Analytical Instruments (lab equipment), Specialty Diagnostics (clinical testing products), and Laboratory Products and Biopharma Services (contract manufacturing and research services for drug companies).

Thermo Fisher Scientific is a $166.4 billion life sciences and laboratory equipment company that provides instruments, reagents, diagnostics, and contract manufacturing services to pharmaceutical, biotech, and research customers worldwide [Yahoo Finance]. The company serves as a critical infrastructure provider for drug development, with recent growth driven by expanding bioprocess services, new laboratory facilities in Sweden, and partnerships to manufacture oncology drugs [Yahoo Finance]. Despite solid fundamentals, the stock has significantly underperformed the market over the past year, rising only 8.3% compared to the S&P 500's 25.2% gain [Yahoo Finance].

Thermo Fisher shows solid profitability with moderate leverage, though return on capital and stock performance lag expectations.

En bref AI analysisConfiance 8/10

Score Sentinellis

6.8/10

Moderate concerns

Capitalisation boursière

$166.4B

Chiffre d'affaires (12 mois)

$44.6B

II · Actualités récentes

Ce qui a fait bouger le cours

6 stories · ranked by relevance

  • macro2026-05-20

    Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day

    Yahoo Finance

  • macro2026-05-19

    Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG

    Yahoo Finance

  • macro2026-05-18

    Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading

    Yahoo Finance

  • macro2026-05-18

    Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps

    Simply Wall St

  • macro2026-05-18

    Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden

    Yahoo Finance

  • macro2026-05-18

    Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone

    Simply Wall St

Premium · gratuit avec tout compte

The stock has badly underperformed the market, gaining only 8.3% over the past year while the S&P 500 rose 25.2%, and is down 24.4% year-to-date versus an 8.1% market gain [Yahoo Finance]. This persistent weakness suggests investor concerns about growth trajectory or valuation.

1 sur 4 risques dans ce rapport

Risques

4

Opportunités

5

Signaux d'alerte

1

Direction

10

19 autres constats dans le rapport complet — gratuit avec tout compte.

Débloquer l'analyse complète de Thermo Fisher Scientific Inc

Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.

  • 4 risques, 5 opportunités et 1 signal d'alerte — chacun avec sa source
  • Plus de 100 indicateurs financiers avec graphiques et comparaisons
  • Résumés d'actualités complets avec liens vers les sources
  • Équipe dirigeante et rémunération
  • Export PDF pour la lecture hors ligne
Débloquer les 10 constats3 rapports gratuits · sans carte

III · Entreprises similaires

À lire également

Same sector · Healthcare or comparable health

L'ajouter à votre liste ?

Read three companies free. Sans carte.

Obtenir 3 rapports gratuits